Gabapentin
Product Images NDC 64725-0126

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 64725-0126). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tya Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula Gabapentin (522c5010 38dd 4f7f B251 0c8dd50e1f35 01)

Chemical structure of gabapentin depicting a cyclohexane ring with attached amino (H2N) and carboxyl (COOH) functional groups. The diagram shows the molecular framework typical for gabapentin's chemical composition.*

FDA Label Image

Figure 1 (522c5010 38dd 4f7f B251 0c8dd50e1f35 02)

A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks, including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin group shows a significant decrease in pain scores compared to placebo (p < 0.01).*

FDA Label Image

Figure 2 (522c5010 38dd 4f7f B251 0c8dd50e1f35 03)

A line graph showing mean pain scores over 7 weeks for placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day groups. The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Both Gabapentin groups show a greater reduction in pain scores compared to placebo, with statistical significance indicated at multiple time points.*

FDA Label Image

Figure 3 (522c5010 38dd 4f7f B251 0c8dd50e1f35 04)

A bar chart comparing the percentage of responders at endpoint in two studies for Gabapentin (GBP) dosages 3600 mg, 1800 mg, and 2400 mg against placebo (PBO). Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg, while Study 2 shows 14% for placebo and 32% and 34% for GBP 1800 mg and 2400 mg, respectively. Statistical significance levels are indicated above the bars.*

FDA Label Image

Figure 4 (522c5010 38dd 4f7f B251 0c8dd50e1f35 05)

A comparative scatter plot illustrating percentage difference versus daily dose in milligrams for Gabapentin across three studies labeled a, b, and c. The horizontal axis represents daily dose ranging from 600 mg to 1800 mg, while the vertical axis shows difference percentages from 2% to 22%. Each study is represented by distinct markers: study a with black squares, study b with gray squares, and study c with white squares.*

FDA Label Image

Glenmark Logo (522c5010 38dd 4f7f B251 0c8dd50e1f35 06)

FDA Label Image

Glenmark Logo (522c5010 38dd 4f7f B251 0c8dd50e1f35 07)

FDA Label Image

Label Image (64725 0126)

Label for Gabapentin 600 mg tablets, bottle of 100 tablets. The manufacturer is Glenmark, and the product is repackaged by TYA Pharmaceuticals, located at 2930 Crescent Dr., Tallahassee, FL 32301. The label includes a barcode and indicates the dosage information is on the package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.